Orkambi (Lumacaftor/IVacaftor) Patent Expiration, LOE Window & CMS Spending

Orkambi (Lumacaftor/IVacaftor) by Vertex Pharmaceuticals: FDA Orange Book core substance LOE 2031-03-20 (last listed 2031-06-11), 0 AB generics, $23.3M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorVertex Pharmaceuticals
FDA Application & PathwayN206038 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2031-03-20
Last Listed Patent or Exclusivity Date2031-06-11
Orange Book Patents (*PED Extensions)46 patents (23 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$23.3M
2024 Medicare Part D Spend$634K
2024 Medicaid Spend$22.7M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Vertex Pharmaceuticals across sibling Meru public-data platforms.